Wegovy and OzemPIC can help treat common liver disease
propagandaAccording to a new article, the main component of The best drug sales I can help people Treatment of severe liver disease Before becoming a threat to life. The results published on Wednesday in Revist ‘New EnglandIt is the latest evidence that medications that are slimming such as Ozmpic or Wegovy can help treat other health problems as well as type 2 diabetes and obesity, which is currently approved in the European Union.
the Semaglutida It belongs to a category of drugs called GLP-1 receptors, which works by suppressing appetite. but Investigations indicate This can also help in various problems such as addiction, blood clotting and dementia. Now, the new study shows that it can be an applicable treatment for the patients they suffer from Steatoh gulfs EMA, which occurs when fat accumulates in the liver and causes inflammation and scars.
If not, it can develop into CirrhosisAnd it is an advanced liver damage and irreversible. Hormones are not associated with alcohol, but to obesity, type 2 diabetes and high blood pressure. The clinical experience of the advanced stage was funded by the drugs Novo NordskWhich sells Smaglutida as Ozmpic and Wegovy. Participate in it 800 patients suffer from fibrosis and liver Moderate or advanced, i.e. the accumulation of scar tissue in the liver.
Good results after 72 weeks
After 72 weeks, 33 % of patients who took Smaglutida Once a week, they suffered from improvements in both inflammation and liver healing, compared to 16 % of those who received imaginary treatment or fictional treatment. Regarding the inflammation and separate recovery, about 63 % of patients who took permanent inflammation of inflammation and noticed 37 % of improvement in recovery.
This is compared to 34 % and 22 %, respectively, from the imaginary drug group. In addition, the patients who took Smaglutida lost an average of 10.5 % of body weight. Study results They are “very exciting”Deby Shukros, the doctor, a professor of liver and chronic liver failure of the King’s College in London (UK) and Attorney General for the European Year to study the liver.
But not all merits are performed, because drug patients and placebo are also They received a lifestyle advice And recommendations on how to control your other health problems. Nearly half of the study participants suffered from type 2 diabetes and three in four were obese.
According to Shukros, the fact that 34 % of the participants in the pharmaceutical group reduced hepatitis – without losing much weight – indicates this Lifestyle changes can also perform An important role in helping people control the mash.
“This is important, because any treatment is authorized to go with a moderate to dangerous fibrosis It should be used with lifestyle interventionsHe told “Euronews Health” Shawcross, who did not participate in the new study. In the article, patients who took Semaglutida also suffered some side effects, such as nausea, diarrhea, constipation and vomiting. The harmful effects They made 2.6 % of them leave the study.
A new potential treatment for the mash
When Novo Nordisk published the main results of the article in November 2024, the company said I would like to ask the organizational authorities of the European Union and the United States. This will approve the medicine for patients with mash in the middle of -2025. At that time, Martin Holst Lang, doctor and CEO of the company, said the drug could help cover A. “An important need is unnecessary” Of patients with mash.
A spokesman for Novo Nordsk did not respond on Wednesday to request the “Euronews Health” in which he demanded the update of the final dates. In the European Union, no medication has been approved yet To treat mash, but others have been promising in recent years. For example, ResMAROM helped improve liver healing in an advanced experience in the stage that was published last year and received green light in the United States.
It is still taught by the European Union’s organizational authorities. Shukros said it was too early to know If Smaglutida can change the rules of the game For patients with mash, but “it is undoubtedly a powerful tool in the arsenal of the liver specialist if used with lifestyle modification programs.”
He pointed out that many people who take medications for weight loss They do not make changes in their lifestyle They can help them improve their health if they stop taking them, which is “an important concern for all of us.” “There are many motives for patients who are undergoing a document in the tests to perform Positive modifications in your lifestyle “It may not be seen in the real world,” Shakros said.
